Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy

Fig. 6

CSMD1-expressing tumorspheres are more sensitive to chemotherapy agents. A MDA-MB-231 and (B) BT-20 tumorspheres were pre-treated with 35 μM of GEF followed by 2 μM of doxorubicin or epirubicin for two days (MDA-MB-231) or 8 μM of doxorubicin and epirubicin for one day (BT-20). Early and late apoptotic cells were detected using Annexin V and Zombie Aqua staining. Bar graphs showing percentages of early and late apoptotic cells. All experiments were repeated at least 3 times with bars indicating mean ± SD, grey circles correspond to independent data points for CTRL and CSMD1 groups, respectively. A two-way ANOVA Bonferroni’s multiple comparisons test was used when comparing CTRL and CSMD1 groups in different treatments (* < 0.05, ** < 0.01, *** < 0.001)

Back to article page